This article is more than 5 years old. Information may no longer be current.
Cisplatin-based chemotherapy conferred better outcomes than capecitabine-based regimen
Cisplatin-based chemotherapy appeared superior to a capecitabine-based regimen in first-line treatment of metastatic triple-negative breast cancer, according to study results.
Triple-negative breast cancer (TNBC) may be more sensitive to platinum. Because of this, researchers compared platinum-based regimen with non-platinum treatment in the first-line therapy of advanced TNBC.
The researchers enrolled 53 women who had not undergone prior treatment for metastatic disease. Researchers randomly assigned patients (1:1) to receive either docetaxel/cisplatin or docetaxel/capecitabine (Xeloda, Roche) for up to six cycles until disease progression or unacceptable toxicity.
Objective response rate served as the primary endpoint. Secondary endpoints included PFS and OS.
Median follow-up was 24 months.
Researchers observed a higher objective response rate (63% vs. 15.4%; P=.001), longer PFS (10.9 months vs. 4.8 months; P<.001) and longer OS (32.8 months vs. 21.5 months; P=.027) among patients assigned to docetaxel/cisplatin.
Adverse effects were similar between the two groups, although patients assigned to docetaxel/cisplatin experienced higher rates of grade 3 or 4 vomiting and grade 2 or 3 hand-foot syndrome.
The findings suggest a large-scale study designed to compare the two regimens is warranted, the researchers wrote.
Disclosure: The researchers report no relevant financial disclosures.